Live Chat

Vir Biotechnology 거래 VIR

매도
 매수

VirBiotechnology 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

최신 뉴스

Christine Voong 2025 Jan 15, 10:45

GBP Rate Update: Exploring the GBP to USD Forecast for 2025

GBP USD Forex
Christine Voong 2025 Jan 15, 08:00

Elon Musk’s TikTok Acquisition Rumors | TikTok Viewers Insights | Markets.com

Stocks Tech Shares
Frances Wang 2025 Jan 14, 16:00

Stock Market Today: Asian Stocks’ Mixed Performance before Inflation Data

Stocks
Gold price graph
Tommy Yap 2025 Jan 14, 16:00

Morning Note: PPI Pressures USD, Eyes on CPI for Fed's Next Move

Morning Note USD Forex Gold Fed
Ahmed Abushar 2025 Jan 14, 16:00

Bitcoin’s Recovery: Why Is Crypto Going Up Amid Market Jitters?

Cryptocurrencies ETFs CFD Trading
Frances Wang 2025 Jan 13, 16:00

Potential TikTok ban: Chinese RedNote tops US app store

Stocks
Frances Wang 2025 Jan 13, 16:00

Phio stock surged 330%: Phio reports 100% tumor clearance

Stocks
Frances Wang 2025 Jan 13, 16:00

Oil Price Today: Oil Hits Four-Month High Following US Sanctions on Russia

Commodities

정보

스프레드

0.08

스프레드(%)

0.7442 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 개장

수요일

14:31 - 20:59

월요일

14:31-20:59

화요일

14:31-20:59

목요일

14:31-20:59

금요일

14:31-20:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

1666410112

발행 주식 수

137720000

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-3.42

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments
Trustpilot
Live Chat